ENETS 2021 VIRTUAL

18th Annual ENETS Conference
for the Diagnosis and Treatment
of Neuroendocrine Tumor Disease

25 – 27 February 2021

SCIENTIFIC PROGRAMME

Time Zone: Central European Time (CET)
18th Annual ENETS Virtual Conference

Welcome Letter

Dear Friends and Colleagues,

We would like to welcome you to our live and virtual 18th Annual ENETS Conference, 25 – 27 February 2021! This is the second time in a row that ENETS has hosted its annual conference virtually due to the COVID pandemic. Although we had hoped this year to be able to host a physical conference, we feel that we have taken all the steps necessary to ensure that this event provides you with ample educational material, as well as opportunities to exchange, learn and even network!

Over the course of three days, we will present the most up-to-date aspects of neuroendocrine neoplasms (NEN) diagnostics and therapeutics.

We are excited to open the conference with a plenary lecture on immunotherapy in cancer and how to apply immunotherapy in NET. This will be followed by updates on the pathology of neuroendocrine neoplasms, and special consideration in the field of surgery applied in NEN. Other plenary sessions will focus on nuclear medicine diagnostic and therapy, recent results from clinical trials and key ongoing trials, treatment outcomes, as well as challenges and controversies in the management of NEN.

A second plenary lecture will highlight radiomics in NEN. Special sessions will address new developments and up-to-date management of lung NEN and carcinoid heart disease. ENETS is looking to the future and has two dedicated abstract sessions on new results in clinical and basic science.

ENETS is hosting this year’s collaborative session with the European Society of Endocrinology (ESE). We appreciate our ESE colleagues will be present for this session that is dedicated to MEN-1, medullary thyroid carcinoma, and the management of bone involvement in NENs.

Other highlights include a review of basic science and abstract highlights. Furthermore, exciting extra sessions will be offered on Friday, 26 February 2021, including a collaborative session with the International Neuroendocrine Cancer Alliance (INCA) on patient-driven research and a nurse and dietitian symposium.

Videos will be made available on My ENETS for conference participants after the meeting. Keep up to date with all the news on enetsconference.org.

Chat rooms may allow interaction with your peers and experts during the main meeting.

On behalf of the ENETS Executive Committee we are very much looking forward to your participation at this year’s virtual event, and we hope to be able to see you again in person in the very near future.

Warm regards,

Yours

Marianne Ellen Pavel

ENETS Chair
Thursday, 25.02.2021

Welcome
Time: Thursday 10:45 - 11:00
Speaker: Marianne Ellen Pavel, GER

Plenary lecture
Time: Thursday 11:00 - 11:30
Moderator: Marianne Ellen Pavel, GER
11:00 - 11:30  Immunotherapy in cancer - How to apply immonuthery in NET
Wolf Hervé Fridman, FRA

Pathology of neuroendocrine neoplasms (NEN): Focus on heterogeneity and progression
Time: Thursday 11:30 - 12:45
Moderator: Anne Couvelard, FRA / Marianne Ellen Pavel, GER
11:30 - 11:45  New subcategories of NENs: Update on WHO and markers
Massimo Milione, ITA
11:45 - 12:00  Spatial and temporal heterogeneity in NET: A clue to understand (naïve and
chemoinduced) tumor progression?
Jerome Cros, FRA
12:00 - 12:15  Is the molecular transition from NET to NEC-like clinically relevant?
Leonidas Apostolidis, GER
12:15 - 12:30  Clinical case discussion
Leonidas Apostolidis, GER / Jerome Cros, FRA
12:30 - 12:45  Discussion

BREAK
Time: Thursday 12:45 - 13:30

Best abstracts: Clinical science
Time: Thursday 13:30 - 14:45
Moderator: Eva Tiensuu Janson, SWE / Thomas Walter, FRA
13:30 - 13:40  Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors. An international double-blind, placebo-controlled randomized phase II. Prodigie 31 REMINET. A FFCD study
Côme Lepage, FRA
13:40 - 13:45  Q & A
Sagar Rakshit, USA
13:53 - 13:57  Q & A
13:57 - 14:05  Automatized hepatic tumor volume analysis of neuroendocrine liver metastases by Gd-EOB MRI - A deep learning model to support multidisciplinary cancer conference decision making
Uli Fehrenbach, GER
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:05 - 14:09</td>
<td>Q &amp; A</td>
</tr>
</tbody>
</table>
| 14:09 - 14:17 | Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results  
                      Marianne Ellen Pavel, GER                                             |
| 14:17 - 14:21 | Q & A                                                                   |
| 14:21 - 14:29 | hPG80 (Circulating Progastrin), a novel blood-based biomarker for detection of well-differentiated neuroendocrine tumors  
                      Aman Chauhan, USA                                                      |
| 14:29 - 14:33 | Q & A                                                                   |
| 14:33 - 14:41 | Artificial intelligence applications in 68Ga-DOTA PET/CT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC  
                      Riccardo Laudicella, ITA                                               |
| 14:41 - 14:45 | Q & A                                                                   |

### Surgery and neoadjuvant therapy in NEN

**Time:** Thursday 14:45 - 15:45  
**Moderator:** Massimo Falconi, ITA / Eva Tiensuu Janson, SWE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:45 - 15:00 | Pan-NET and Si-NET - Current role of robotic-assisted resections  
                      Detlef Bartsch, GER                                                   |
| 15:00 - 15:15 | Pan-NET and Si-NET - How to define locally borderline or not resectable?  
                      Marie-Pierre Vullierme, FRA                                           |
| 15:15 - 15:30 | Pan-NET and Si-NET - Is there a place for downsizing or neoadjuvant therapy in locally borderline or not resectable tumors?  
                      Stefano Partelli, ITA                                                  |
| 15:30 - 15:45 | Is there a place for surgery in NEC G3?  
                      James Howe, USA                                                        |

### BREAK

**Time:** Thursday 15:45 - 16:00

### ENETS / European Society of Endocrinology (ESE)

**Time:** Thursday 16:00 - 17:15  
**Moderator:** Simona Glasberg, ISR / Beata Kos-Kudla, POL

**Swinging between Hormones and NENs: Cutting-edge Developments**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:00 - 16:20 | Searching for MEN - Unmet clinical needs and challenges in genetic counselling  
                      Gerlof Valk, NED                                                       |
| 16:20 - 16:40 | MTC: Current challenges and unmet needs - New players on the stage  
                      Mimi I. Hu, USA                                                        |
| 16:40 - 17:00 | Management of bone involvement in NENs - Whom, when, what, how much?  
                      Maria Luisa Brandi, ITA                                               |
| 17:00 - 17:15 | Discussion                                                              |

### Closing comments

**Time:** Thursday 17:15 - 17:30
**Speaker:** Marianne Ellen Pavel, GER

**Satellite Symposium I - Industry-sponsored**

**Time:** Thursday 17:30 - 19:00
**Friday, 26.02.2021**

**Women in NET: Launch Meeting**  
*Time:* Friday 09:00 - 10:30  
*Moderator:* Marianne Ellen Pavel, GER / Simona Glasberg, ISR / Beata Kos-Kudła, POL  
Rocio Garcia-Carbonero, ESP / Eva Tiensuu Janson, SWE

**Welcome**  
*Time:* Friday 10:45 - 10:55  
*Speaker:* Marianne Ellen Pavel, GER

**Plenary lecture**  
*Time:* Friday 10:55 - 11:25  
*Moderator:* Dermot O’Toole, IRL  
10:55 - 11:25  
**Radiomics in NEN**  
Clarisse Dromain, SUI

**Nuclear medicine diagnostic and therapy (PARALLEL SESSION)**  
*Time:* Friday 11:25 - 12:45  
*Moderator:* Lisa Bodei, USA / Anders Sundin, SWE

  **Functional imaging** (11:25 - 12:05)

11:25 - 11:45  
**FDG PET for all NET?**  
Valentina Ambrosini, ITA / Andreas Kjaer, DEN  
Debate: Affirmative speaker/Negative speaker

11:45 - 12:05  
**Functional imaging as a predictor of PRRT response: What is robust?**  
Vikas Prasad, GER

  **New approaches to optimise treatments for PRRT** (12:05 - 12:45)

12:05 - 12:30  
**New tracers and combination and sequential therapies**  
Damian Wild, SUI

12:30 - 12:45  
**Discussion**

**ENETS Nurse & Dietitian Symposium (PARALLEL SESSION)**  
*Time:* Friday 11:25 - 12:45  
*Chair:* Wanda Geilvoet, NED

11:25 - 11:30  
**Welcome & introduction**  
Wanda Geilvoet, NED

11:30 - 11:50  
**Need to know - A crash course in neuroendocrine tumor imaging**  
Anders Sundin, SWE

11:50 - 12:00  
**Research - Complementary and alternative medicine in NETs**  
Mette Borre, DEN

12:00 - 12:10  
**Reach out - How to reach the rare NET-nurses?**  
Sophie Noble, GBR
Case studies (12:10 - 12:40)

12:10 - 12:25  Insulinoma - A complex dilemma  
Deborah Pitfield, GBR

12:25 - 12:40  Long term NET patient - Thinking outside the box  
Wendy Martin, GBR

12:40 - 12:45  Closing Comments  
Wanda Geilvoet, NED

BREAK

Time: Friday 12:45 - 13:30

Recent results from clinical trials and key ongoing trials

Time: Friday 13:30 - 15:00  
Moderator: Rocio García-Carbonero, ESP / John Ramage, GBR

13:30 - 13:50  Clinical trials design revisited - Future strategies and endpoints  
Simron Singh, CAN

13:50 - 14:05  Clinical trials in Europe  
Enrique Grande, ESP

14:05 - 14:20  Clinical trials in the Americas  
Emily Bergsland, USA

14:20 - 14:35  Clinical trials in Asia and Australia  
Jie Chen, CHN

14:35 - 15:00  Discussion

BREAK

Time: Friday 15:00 - 15:15

Carcinoid heart disease

Time: Friday 15:15 - 16:15  
Moderator: Christos Toumpanakis, GBR / Jerome Zacks, USA

15:15 - 15:25  Value of biomarkers for diagnosis and follow-up  
Stephane Ederhy, FRA

15:25 - 15:35  Optimised therapeutic and perioperative management  
Hans Hofland, NED

15:35 - 15:45  Percutaneous or surgical valve replacement - When is the right time?  
Anders Albåge, SWE

15:45 - 15:55  Challenges in the clinical management of CHD  
Simona Glasberg, ISR

15:55 - 16:15  Discussion

Best abstracts: Translational research / Basic science (PARALLEL SESSION)

Time: Friday 16:15 - 17:30
Moderator: Justo P. Castaño, ESP / Aurel Perren, SUI

16:15 - 16:25  A patient derived organoid model of neuroendocrine neoplasms enables long-term growth in vitro of low grade tumors and reveals therapeutic vulnerabilities
   Talya Dayton, NED

16:25 - 16:30  Q & A

16:30 - 16:40  A molecular map of lung neuroendocrine neoplasms
   Emilie Mathian, FRA

16:40 - 16:45  Q & A

16:45 - 16:53  Immune heterogeneity and cascade of changes in subtypes of pancreatic neuroendocrine tumors
   Anguraj Sadanandam, GBR

16:53 - 16:56  Q & A

16:56 - 17:04  Establishment of neuroendocrine neoplasms organoid biobank enables genotype-phenotype mapping
   Kenta Kawasaki, JPN

17:04 - 17:07  Q & A

17:07 - 17:15  Transcriptomic deconvolution of neuroendocrine neoplasms predicts clinically relevant characteristics
   Raik Otto, GER

17:15 - 17:18  Q & A

17:18 - 17:26  Splicing machinery dysregulation in low grade pulmonary carcinoids
   Ricardo Blázquez-Encinas, ESP

17:26 - 17:29  Q & A

17:29 - 17:30  Closing comments

INCA/ENETS Symposium - Patient impact on improving NET research and time to diagnosis (PARALLEL SESSION)

Time: Friday 16:15 - 17:30
Chairs: Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

16:15 - 16:20  Welcome and introductions from ENETS and INCA
   Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

Part 1: Improving NET research (16:20 - 16:50)

16:20 - 16:23  Setting the scene: Why is patient-led/driven research instrumental?
   Teodora Kolarova, BUL

16:23 - 16:50  Best practice examples of patient involvement in research

16:23 - 16:30  SCAN
   Mark McDonnell, IRL

16:30 - 16:35  INCA boot camp for research advocates
   Jackie Herman, CAN

16:35 - 16:40  Cell Line Project - Tumor tissue donation to facilitate research
   Elyse Gellerman, USA

16:40 - 16:50  The value of patient-driven research
   Jaume Capdevila, ESP
Part 2: Improving time to diagnosis (16:50 - 17:25)

16:50 - 16:58  Early diagnosis challenges as reported in SCAN & SCAN II launch  
Sugandha Dureja, IND

16:58 - 17:05  Impact of misdiagnosis on healthcare systems and patients - Understanding the barriers to early diagnosis  
Catherine Bouvier, GBR

17:05 - 17:10  Optimal care pathway for NETs  
Simone Leyden, AUS

17:10 - 17:20  NEN misdiagnosis and late diagnosis - How can we have a positive impact on changing the facts?  
Dermot O'Toole, IRL

17:20 - 17:25  Questions & answers

17:25 - 17:30  Take home messages and closing comments  
Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

Closing comments

Time: Friday 17:30 - 17:45  
Speaker: Marianne Ellen Pavel, GER

Satellite Symposium II - Industry-sponsored

Time: Friday 17:45 - 19:15
Saturday, 27.02.2021

Welcome
Time: Saturday 10:45 - 10:50
Speaker: Marianne Ellen Pavel, GER

Treatment outcomes
Time: Saturday 10:50 - 11:50
Moderator: Antongiulio Faggiano, ITA / Anja Rinke, GER
10:50 - 11:05 Psychological aspects - Basic conditions and impact of therapy in carcinoid syndrome
John Ramage, GBR
11:05 - 11:20 Sex differences in patients with neuroendocrine neoplasms
Pamela Kunz, USA
11:20 - 11:35 Treatment outcome in NEN patients with diabetes - Basic conditions and impact of therapy
Sara Pusceddu, ITA
11:35 - 11:50 Discussion

Challenges and controversies (ENETS / NextGEN ENETS)
Time: Saturday 11:50 - 12:50
Moderator: Philippe Ruszniewski, FRA / Juan Valle, GBR
11:50 - 12:05 Where is the place for radiotherapy in the management of NEN?
David Chan, AUS
12:05 - 12:20 NET and pregnancy/fertility
Angela Lamarca, GBR
12:20 - 12:35 Intra-abdominal complications of NET (occlusion, peritoneal, carcinomatosis, fibrosis, ischemia) - How to prevent and how to treat?
Marc Peeters, BEL
12:35 - 12:50 Effects on investigations and therapy during COVID pandemic
Nicola Fazio, ITA

Satellite Symposium III - Industry-sponsored
Time: Saturday 12:50 - 13:50

Pulmonary NET
Time: Saturday 13:50 - 15:05
Moderator: Eric Baudin, FRA / Marco Volante, ITA
13:50 - 14:00 Limitations of the new WHO classification
Aurelie Fabre, IRL
14:00 - 14:10 Bronchial-NEN - What is the adequate extent of resection?
Pier Luigi Filosso, ITA
14:10 - 14:20 Who should receive adjuvant therapy or therapy for residual disease?
Debashis Sarker, GBR
14:20 - 14:35 Systemic therapy of lung carcinoids
Eric Baudin, FRA
14:35 - 14:45  Is there a place for immunotherapy in lung NEN?  
 exponentially, Jaume Capdevila, ESP

14:45 - 15:05  Discussion

**BREAK**

**Time:** Saturday 15:05 - 15:20

**What's new?**

**Time:** Saturday 15:20 - 16:20
**Moderator:** Eric Baudin, FRA / Elisabeth Nieveen van Dijkum, NED

15:20 - 15:50  Translational NET update - Review of the year  
Justo P. Castaño, ESP

15:50 - 16:20  ENETS abstracts highlights  
Nicholas Simon Reed, GBR

**Awards Ceremony - Best abstracts 2021**

**Time:** Saturday 16:20 - 16:35
**Moderator:** Marianne Ellen Pavel, GER / Nicholas Simon Reed, GBR

**Closing comments**

**Time:** Saturday 16:35 - 16:45
**Speaker:** Marianne Ellen Pavel, GER
<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>First Name</th>
<th>Last Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALBAGE</td>
<td>Anders</td>
<td></td>
<td>SWE</td>
</tr>
<tr>
<td>AMBROSINI</td>
<td>Valentina</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>APOSTOLIDIS</td>
<td>Leonidas</td>
<td></td>
<td>GER</td>
</tr>
<tr>
<td>BARTSCH</td>
<td>Detlef</td>
<td></td>
<td>GER</td>
</tr>
<tr>
<td>BAUDIN</td>
<td>Eric</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>BERGSLAND</td>
<td>Emily</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>BLÁZQUEZ-ENCINAS</td>
<td>Ricardo</td>
<td></td>
<td>ESP</td>
</tr>
<tr>
<td>BODEI</td>
<td>Lisa</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>BOUVERE</td>
<td>Mette</td>
<td></td>
<td>DEN</td>
</tr>
<tr>
<td>BRANDI</td>
<td>Maria Luisa</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>CAPDEVILA</td>
<td>Jaume</td>
<td></td>
<td>ESP</td>
</tr>
<tr>
<td>CASTANO</td>
<td>Justo P.</td>
<td></td>
<td>ESP</td>
</tr>
<tr>
<td>CHAN</td>
<td>David</td>
<td></td>
<td>AUS</td>
</tr>
<tr>
<td>CHAHAN</td>
<td>Aman</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>CHEN</td>
<td>Jie</td>
<td></td>
<td>CHN</td>
</tr>
<tr>
<td>COUVELLARD</td>
<td>Anne</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>CROS</td>
<td>Jerome</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>DAYTON</td>
<td>Talya</td>
<td></td>
<td>NED</td>
</tr>
<tr>
<td>DROMAIN</td>
<td>Clarisse</td>
<td></td>
<td>SUI</td>
</tr>
<tr>
<td>DUREJA</td>
<td>Sugandha</td>
<td></td>
<td>IND</td>
</tr>
<tr>
<td>EDERHY</td>
<td>Stephane</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>FABRE</td>
<td>Aurelie</td>
<td></td>
<td>IRL</td>
</tr>
<tr>
<td>FAGGIANO</td>
<td>Antongiulio</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>FALCONI</td>
<td>Massimo</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>FAZIO</td>
<td>Nicola</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>FEHRENBACH</td>
<td>Uli</td>
<td></td>
<td>GER</td>
</tr>
<tr>
<td>FILOSOSS</td>
<td>Pier Luigi</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>FRIDMAN</td>
<td>Wolf Hervé</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>GARCIA-CARBONERO</td>
<td>Rocio</td>
<td></td>
<td>ESP</td>
</tr>
<tr>
<td>GEILVOET</td>
<td>Wanda</td>
<td></td>
<td>NED</td>
</tr>
<tr>
<td>GELLERMANN</td>
<td>Elyse</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>GLASBERG</td>
<td>Simona</td>
<td></td>
<td>ISR</td>
</tr>
<tr>
<td>GRANDE</td>
<td>Enrique</td>
<td></td>
<td>ESP</td>
</tr>
<tr>
<td>HERMAN</td>
<td>Jackie</td>
<td></td>
<td>CAN</td>
</tr>
<tr>
<td>HOFLAND</td>
<td>Hans</td>
<td></td>
<td>NED</td>
</tr>
<tr>
<td>HOWE</td>
<td>James</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>HU</td>
<td>Mimi l.</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>KAWASAKI</td>
<td>Kenta</td>
<td></td>
<td>JPN</td>
</tr>
<tr>
<td>KJÆR</td>
<td>Andreas</td>
<td></td>
<td>DEN</td>
</tr>
<tr>
<td>KOLAROVA</td>
<td>Teodora</td>
<td></td>
<td>BUL</td>
</tr>
<tr>
<td>KOS-KUDLA</td>
<td>Beata</td>
<td></td>
<td>POL</td>
</tr>
<tr>
<td>KUNZ</td>
<td>Pamela</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>LAMARCA</td>
<td>Angela</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>LAUDICELLA</td>
<td>Riccardo</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>LEPAGE</td>
<td>Côme</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>LEYDEN</td>
<td>Simone</td>
<td></td>
<td>AUS</td>
</tr>
<tr>
<td>MARTIN</td>
<td>Wendy</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>MATHIAN</td>
<td>Emilie</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>MCDONNELL</td>
<td>Mark</td>
<td></td>
<td>IRL</td>
</tr>
<tr>
<td>MILIONE</td>
<td>Massimo</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>NIEVEEN VAN DIJKUM</td>
<td>Elisabeth</td>
<td></td>
<td>NED</td>
</tr>
<tr>
<td>NOBLE</td>
<td>Sophie</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>O‘TOOLE</td>
<td>Dermot</td>
<td></td>
<td>IRL</td>
</tr>
<tr>
<td>OTTO</td>
<td>Raik</td>
<td></td>
<td>GER</td>
</tr>
<tr>
<td>PARTELLI</td>
<td>Stefano</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>PAVEL</td>
<td>Marianne</td>
<td></td>
<td>BEL</td>
</tr>
<tr>
<td>PEETERS</td>
<td>Marc</td>
<td></td>
<td>SUI</td>
</tr>
<tr>
<td>PERREN</td>
<td>Aurel</td>
<td></td>
<td>SUI</td>
</tr>
<tr>
<td>PITFIELD</td>
<td>Deborah</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>PRASAD</td>
<td>Vikas</td>
<td></td>
<td>GER</td>
</tr>
<tr>
<td>PUSCEDDU</td>
<td>Sara</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>RAKSHIT</td>
<td>Sagar</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>RAMAGE</td>
<td>John</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>REED</td>
<td>Nicholas</td>
<td></td>
<td>SUI</td>
</tr>
<tr>
<td>RINKE</td>
<td>Anja</td>
<td></td>
<td>GER</td>
</tr>
<tr>
<td>RUSZNIEWSKI</td>
<td>Philippe</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>SADANANDAM</td>
<td>Anguraj</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>SARKER</td>
<td>Debashis</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>SINGH</td>
<td>Simron</td>
<td></td>
<td>CAN</td>
</tr>
<tr>
<td>SORBYE</td>
<td>Halfdan</td>
<td></td>
<td>NOR</td>
</tr>
<tr>
<td>SUNDIN</td>
<td>Anders</td>
<td></td>
<td>SWE</td>
</tr>
<tr>
<td>TIENSUUS JANSON</td>
<td>Eva</td>
<td></td>
<td>SWE</td>
</tr>
<tr>
<td>TOUMPANAKIS</td>
<td>Christos</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>VALK</td>
<td>Gerlof</td>
<td></td>
<td>NED</td>
</tr>
<tr>
<td>VALLE</td>
<td>Juan</td>
<td></td>
<td>GBR</td>
</tr>
<tr>
<td>VOLANTE</td>
<td>Marco</td>
<td></td>
<td>ITA</td>
</tr>
<tr>
<td>VULLIERME</td>
<td>Marie-Pierre</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>WALTER</td>
<td>Thomas</td>
<td></td>
<td>FRA</td>
</tr>
<tr>
<td>WILD</td>
<td>Damian</td>
<td></td>
<td>SUI</td>
</tr>
<tr>
<td>ZACKS</td>
<td>Jerome</td>
<td></td>
<td>USA</td>
</tr>
</tbody>
</table>
European Neuroendocrine Tumor Society e.V. (ENETS)
Langenbeck-Virchow-Haus
Luisenstr. 58/59
10117 Berlin
VAT Nr.: DE252810143
Amtsgericht Charlottenburg: VR 23838 B
www.enets.org | info@enets.org
ENETS SPONSORS AND SUPPORTERS 2021

ENETS gratefully acknowledges the generous support of its sponsors and supporters for the ENETS virtual conferences in 2021:

Platinum Sponsor

IPSEN
Innovation for patient care

Legacy Sponsor

Advanced Accelerator Applications
A Novartis Company

Silver Sponsor

Hutchison Medi Pharma

Bronze Sponsor

Pfizer

Supporters